Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone in Patients With Advanced Androgen-Independent Prostate Cancer (AI-PCa)

NCT00059631 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00059631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00059631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone in Patients With Advanced Androgen-Independent Prostate Cancer (AI-PCa)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
March 20, 2003
Completion date
June 17, 2015
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer